Genea Biocells US, Inc.

Genea Biocells is a neuromuscular disease-focused company based on a proprietary technology platform for the accelerated development of drugs to treat neuromuscular diseases - typically rare orphan diseases that present an area of particularly high unmet medical need with patients in many cases being children for which no treatment options exist. Genea Biocells developed a proprietary skeletal muscle differentiation method used to generate disease-affected skeletal muscles for disease modeling and drug screening in ways not possible using other methods. Genea Biocells’ screening approach makes use of a highly curated repurposed chemical library of compounds with favorable toxicity profiles, paving an accelerated path for regulatory approval of lead compound hits. This drug development platform led to our current lead programs for facioscapulohumeral dystrophy (FSHD) and spinal muscular atrophy (SMA) as well as discovery-stage programs for Kennedy's disease, LAMA2 congenital muscular dystrophy, and congenital myotonic dystrophy. Genea Biocells is based in San Diego, California and originated from the Australian Genea group, a public, unlisted company that has been operating world leading IVF clinics since 1985.